Black Rock Inc. Bolt Biotherapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 267,068 shares of BOLT stock, worth $165,582. This represents 0.0% of its overall portfolio holdings.

Number of Shares

267,068

Previous 254,958 4.75%

Holding current value

$165,582

Previous $356,000 43.82%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.73 - $1.5 $8,840 - $18,165	12,110 Added 4.75%	267,068 $200,000
Q1 2024 May 10, 2024	SELL	$1.01 - $1.4 $2,336 - $3,238	-2,313 Reduced 0.9%	254,958 $356,000
Q4 2023 Feb 13, 2024	SELL	$0.85 - $1.12 $639 - $842	-752 Reduced 0.29%	257,271 $288,000
Q3 2023 Nov 13, 2023	SELL	$0.98 - $1.46 $29,270 - $43,607	-29,868 Reduced 10.37%	258,023 $268,000
Q2 2023 Aug 11, 2023	BUY	$1.27 - $1.95 $17,095 - $26,248	13,461 Added 4.91%	287,891 $368,000
Q1 2023 May 12, 2023	BUY	$1.29 - $1.66 $1,698 - $2,186	1,317 Added 0.48%	274,430 $381,000
Q4 2022 Feb 13, 2023	SELL	$1.26 - $1.51 $214,304 - $256,825	-170,083 Reduced 38.38%	273,113 $355,000
Q3 2022 Nov 14, 2022	SELL	$1.48 - $2.61 $10,559 - $18,622	-7,135 Reduced 1.58%	443,196 $657,000
Q2 2022 Aug 12, 2022	SELL	$1.41 - $2.91 $1.64 Million - $3.38 Million	-1,162,058 Reduced 72.07%	450,331 $918,000
Q1 2022 May 12, 2022	SELL	$2.74 - $4.82 $99,472 - $174,985	-36,304 Reduced 2.2%	1,612,389 $4.42 Million
Q4 2021 Feb 10, 2022	BUY	$4.19 - $13.97 $813,555 - $2.71 Million	194,166 Added 13.35%	1,648,693 $8.08 Million
Q3 2021 Nov 09, 2021	BUY	$11.15 - $18.6 $5.72 Million - $9.54 Million	512,677 Added 54.43%	1,454,527 $18.4 Million
Q2 2021 Aug 11, 2021	BUY	$15.4 - $31.46 $14.5 Million - $29.6 Million	941,850 New	941,850 $14.6 Million

Others Institutions Holding BOLT

# of Institutions

Shares Held

19.1M

Call Options Held

Put Options Held

View Full List

About Bolt Biotherapeutics, Inc.

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $23.3M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

More about BOLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account